Evidence was from an unpublished phase 3 study (n=343) in people with rheumatoid arthritis, which was included in the European public assessment report (EPAR) for Remsima (subcutaneous). For the ...
As a result of the CHMP opinion, if agreed by European Commission (EC), Remsima ® SC 120 mg can be used without IV infusion both for new and existing RA patients. The recommended posology for newly ...
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...
INCHEON, South Korea--(BUSINESS WIRE)--Today, Celltrion Healthcare announced two new data sets on the SC formulation of infliximab, Remsima ® (CT-P13) in IBD, at the European Crohn’s and Colitis ...
The anti-TNF drug works by targeting a protein in the body called TNF-alpha. Celltrion has revealed data from its Remsima SC (infliximab) trials, evaluating a subcutaneous (SC) biosimilar version of ...
The European Commission has authorised the world’s first subcutaneous formulation of infliximab, Remsima SC, for an additional five indications including for use in inflammatory bowel disease and ...
[THE INVESTOR] Celltrion Inc. announced on June 16 that it has applied for a permit to carry out human clinical tests for Remsima SC. Celltrion is an Incheon-based biotechnology firm headed by Seo ...
Celltrion will begin Phase 3 clinical trials for Remsima SC, a biosimilar, in the United States, the company said Wednesday. It recently started to sign up patients who will take part in the tests at ...
Celltrion announced on the 19th that it has received additional approval from Health Canada for the autoimmune disease treatment Remsima SC (generic name infliximab) for the indication of inflammatory ...
South Korean biosimilar firm Celltrion will establish a direct sales network for its drugs worldwide, and specifically Remsima SC -- a subcutaneous version of Remsima -- in an effort to secure price ...
As with all biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, Remsima (subcutaneous) would be prescribed and initiated in secondary care. Unlike intravenous infliximab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results